- Home
- HYMC vs MPLT Comparison
HYMC vs MPLT Comparison
Compare HYMC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYMC | MPLT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | HYMC | MPLT |
|---|---|---|
| Price | $21.24 | $10.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.8M | 511.5K |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 64.26 | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.93 | $9.10 |
| 52 Week High | $58.73 | $40.43 |
Technical Indicators
Market Signals| Indicator | HYMC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.75 |
| Support Level | N/A | $10.67 |
| Resistance Level | N/A | $20.20 |
| Average True Range (ATR) | 0.00 | 0.75 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 9.97 |
Price Performance
Historical ComparisonAbout HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.